文献速递流行病学与生物统计临床试验与 GCP

社区根除幽门螺杆菌预防胃癌:一项整群随机对照试验

Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial.
PubMed 文献 · Nat Med · 2024-07-30

在中国临朐县开展基于社区的整群随机对照优效性干预试验,幽门螺杆菌阳性者随机接受10天四联抗幽门螺杆菌治疗或对症治疗,随访11.8年。抗幽门螺杆菌治疗组胃癌发病率略有降低(HR 0.86,95%CI 0.74-0.99),根除成功者效果更强(HR 0.81,95%CI 0.69-0.96)。

要点

  • 社区人群幽门螺杆菌筛查根除可小幅降低胃癌发病率(HR 0.86,95%CI 0.74-0.99)。
  • 根除成功者胃癌风险降低更明显(HR 0.81,95%CI 0.69-0.96)。
  • 10天治疗期间1345例报告中度不良反应,未观察到严重不可耐受不良事件。

核心结论

  • 研究结果提示,幽门螺杆菌大规模筛查和根除作为胃癌预防的公共卫生政策具有潜力。

研究设计与样本

  • 在中国临朐县开展基于社区的整群随机对照优效性干预试验,纳入13C-尿素呼气试验幽门螺杆菌阳性者。
  • 阳性者随机接受10天四联抗幽门螺杆菌治疗(奥美拉唑20 mg、四环素750 mg、甲硝唑400 mg、枸橼酸铋300 mg)或症状缓解治疗(每日单次奥美拉唑和枸橼酸铋)。
  • 幽门螺杆菌阴性者不接受任何治疗。
  • 共纳入980个村180284名合格参与者,随访11.8年,记录1035例新发胃癌。

主要发现

  • 意向性分析中,接受抗幽门螺杆菌治疗者胃癌发病率略有降低(HR 0.86,95%CI 0.74-0.99)。
  • 幽门螺杆菌根除成功者胃癌风险降低更明显(HR 0.81,95%CI 0.69-0.96),优于治疗失败者。
  • 10天治疗期间1345名参与者报告中度不良反应。
  • 治疗或随访期间未观察到严重不可耐受不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gastric cancer is a leading cause of cancer-related deaths in China. Affecting more than 40% of the world's population, Helicobacter pylori is a major risk factor for gastric cancer. While previous clinical trials indicated that eradication of H. pylori could reduce gastric cancer risk, this remains to be shown using a population-based approach. We conducted a community-based, cluster-randomized, controlled, superiority intervention trial in Linqu County, China, with individuals who tested positive for H. pylori using a 13C-urea breath test randomly assigned to receiving either (1) a 10-day, quadruple anti-H. pylori treatment (comprising 20 mg of omeprazole, 750 mg of tetracycline, 400 mg of metronidazole and 300 mg of bismuth citrate) or (2) symptom alleviation treatment with a single daily dosage of omeprazole and bismuth citrate. H. pylori-negative individuals did not receive any treatment. We examined the incidence of gastric cancer as the primary outcome. A total of 180,284 eligible participants from 980 villages were enrolled over 11.8 years of follow-up, and a total of 1,035 cases of incident gastric cancer were documented. Individuals receiving anti-H. pylori therapy showed a modest reduction in gastric cancer incidence in intention-to-treat analyses (hazard ratio 0.86, 95% confidence interval 0.74-0.99), with a stronger effect observed for those having successful H. pylori eradication (hazard ratio 0.81, 95% confidence interval 0.69-0.96) than for those who failed treatment. Moderate adverse effects were reported in 1,345 participants during the 10-day treatment. We observed no severe intolerable adverse events during either treatment or follow-up. The findings suggest the potential for H. pylori mass screening and eradication as a public health policy for gastric cancer prevention. Chinese Clinical Trial Registry identifier: ChiCTR-TRC-10000979 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Pan KF, Li WQ, Zhang L, et al. Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial. Nat Med. 2024. PMID: 39079993. doi:10.1038/s41591-024-03153-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。